Telix Pharmaceuticals | TLX - Gross Profit On Sales

Stock Price
15.09
Daily Change
-0.12 -0.79%
Monthly
8.17%
Yearly
-43.31%
Q2 Forecast
15.28

Telix Pharmaceuticals reported AUD217.82M in Gross Profit on Sales for its fiscal semester ending in December of 2025.





Gross Profit On Sales Change Date
Cochlear AUD 856.8M 430M Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Integral Diagnostics AUD 226.91M 7.04M Jun/2024
Mayne Pharma AUD 86.13M 18.92M Jun/2025
Medical Developments International AUD 7.35M 7.37M Jun/2025
Mesoblast USD 3.16M 9.61M Dec/2024
Neuren Pharmaceuticals AUD 6.69M 6.37M Jun/2025
Pacific Edge NZD 5.2M 1.75M Jun/2024
Paradigm Biopharmaceuticals AUD -9K 423.94K Jun/2025
Polynovo AUD 61.26M 38M Dec/2025
PYC Therapeutics AUD 5.83M 750K Jun/2025
Ramsay Health Care AUD 549.95M 5.77B Jun/2025
ResMed USD 886.53M 65.71M Dec/2025
Sonic Healthcare AUD 3.92B 3.14B Dec/2024